Recent Chronic Lymphocytic Leukemia News

Venclexta Significantly Reduces Cancer Progression in Chronic Lymphocytic Leukemia

(March 22, 2018)

CancerConnect News: Venclexta (venetoclax) plus Rituxan (rituximab) significantly reduces the risk of cancer progression or death at two years, compared with Treanda (bendustamine) plus Rituxan in the... Continue Reading


Duvelisib; Promising New Treatment Option for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

(September 11, 2017)

Results of the Phase 3 DUO study evaluating duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) have been reported and appear very promising.... Continue Reading


Personalized Cell Therapy Combined with Imbruvica Achieves Complete Remission in High Percentage of Chronic Lymphocytic Leukemia Patients

(June 5, 2017)

Combining the kinase inhibitor Imbruvica (ibrutinib) with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic... Continue Reading


Imbruvica® Effective in Newly Diagnosed and Recurrent Chronic Lymphocytic Leukemia

(July 11, 2016)

Imbruvica (ibrutinib) produces long-lasting anti-cancer responses among patients with newly diagnosed chronic lymphocytic leukemia (CLL), as well as those who have received prior therapies. These results... Continue Reading


FDA Approves Imbruvica for First Line Treatment of Chronic Lymphocytic Leukemia

(March 23, 2016)

Learn more about other FDA Approvals for CLL here. Find more information on CLL here. The US Food and Drug Administration (FDA) approved Imbruvica® (ibrutinib) for first-line use in patients with chronic... Continue Reading


Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings

(December 31, 2015)

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented... Continue Reading


ACP-196 Bruton’s Tyrosine Kinase Inhibitor Safe and Effective for Chronic Lymphocytic Leukemia

(December 17, 2015)

Clinical results published in the New England Journal of Medicine show that the new drug acalabrutinib (ACP-196) is well tolerated and yields high response rates that are durable in patients with chronic... Continue Reading


Zydelig® Combined with Treanda and Rituxan Appears Promising in Treatment of Chronic Lymphocytic Leukemia

(November 18, 2015)

Following the recommendation by an independent Data Monitoring Committee (DMC), Gilead Sciences, Inc today announced that its Phase 3 clinical study evaluating Zydelig® (idelalisib) added to standard... Continue Reading


FDA Approves Gazyva® (Obinutuzumab) Supplemental Biologics License Application with New Data in Previously Untreated Chronic Lymphocytic Leukemia

(January 15, 2015)

Genentech announced that the U.S. Food and Drug Administration (FDA) approved a supplemental biologics license application (sBLA) for Gazyva in combination with chlorambucil chemotherapy in people with... Continue Reading


Promising Activity of Imbruvica Plus Rituxan in High-Risk CLL

(September 10, 2014)

Researchers from MD Anderson Cancer Center recently reported in the journal The Lancet Oncology that the combination of Imbruvica® (ibrutinib) and Rituxan® (rituximab) showed promising activity in... Continue Reading


Next Page »